Straits Times Index
3,269.31 +44.14 (+1.37%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,827.86 +316.17 (+1.91%) FTSE 100
8,061.60 +37.73 (+0.47%) Bitcoin USD
66,244.75 +156.53 (+0.24%) CMC Crypto 200
1,393.47 -21.29 (-1.51%)
Roche Holding AG (RHHVF)
- Zacks
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.
- Zacks
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.
- GlobeNewswire
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)1This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy2The National Comprehensive Cancer Network® (NCCN®) Guidelines recommend routine testing for ALK, EGF
